We promote dialog in the healthcare sector and ensure that costs are saved in a meaningful way. Everyone should benefit from medical progress with the help of IT.
The total capital of CompuGroup Medical is split into 53,734,576 shares with the securities number (WKN) A28890 (ISIN: DE000A288904). Our shares are listed on the Frankfurt Stock Exchange (Prime Standard) as registered shares under the ticker symbol COP (FRA: COP). The shares are traded within the world-wide electronic trading system XETRA. Since September 23, 2013 CGM shares have been listed in the TecDAX, since September 23, 2019 also in the MDAX.
Basic Data
Listing
Börse Frankfurt, Germany, Prime Standard
ISIN
DE000A288904
WKN
A28890
Stock Exchange Symbol
COP
Reuters
COP1n.DE
Bloomberg
COP:GR
Analysts
Broker
Analyst
Rating
Latest Update
Baader Bank
Knut Woller
Reduce
11.02.2021
Berenberg Bank
Charlotte Friedrichs
Hold
16.02.2021
Commerzbank
Florian Treisch
Hold
01.03.2021
Deutsche Bank
Uwe Schupp
Buy
05.02.2021
Kepler Cheuvreux
Nikolas Mauder
Hold
04.02.2021
Landesbank Baden-Württemberg
Mirko Maier
Hold
23.11.2020
STIFEL
Dr. Daniel Grigat
Buy
08.02.2021
Warburg Research
Andreas Wolf
Hold
04.02.2021
Shareholder Structure
Last change: June 25, 2020
Share Buybacks
2021
On February 25, 2021, CompuGroup Medical announced a share buyback program for up to 500,000 shares, a total volume of up to € 40 million and a term until April 30, 2021. The program will be carried out by a credit institution. CompuGroup Medical is thus making use of the authorization granted by the Annual General Meeting on May 15, 2019, to buy back own shares.
Notification regarding start of the share buy-back program
The share buy-back program started on February 26, 2021.
On September 17, 2019, CompuGroup Medical SE announced a share buyback program for up to 930,825 shares, a total volume of up to € 48.4 million and a term until March 31, 2020. The program started on September 18, 2019 and ended on October 30, 2019. CompuGroup Medical SE thus made use of the authorization granted by the Annual General Meeting on May 15, 2019, to buy back own shares. The repurchase was financed from existing cash as well as the use of existing credit facilities.
Disclosure Pursuent to Article 2 Sec. 1 of Commission Delegated Ragulation (EU) No. 2016/1052 supplementing Regulation (EU) No. 596/2014 (MAR) / Purchase of Treasury Shares
On December 13, 2018, CompuGroup Medical SE announced a share buyback program for up to 500,000 shares, a total volume of up to € 20 million and a term until April 30, 2019. The program started on December 17, 2018 and ended on March 19, 2019. CompuGroup Medical SE thus made use of the authorization granted by the Annual General Meeting on May 20, 2015, to buy back own shares. The repurchase was financed from existing cash as well as the use of existing credit facilities.
Disclosure Pursuent to Article 2 Sec. 1 of Commission Delegated Ragulation (EU) No. 2016/1052 supplementing Regulation (EU) No. 596/2014 (MAR) / Purchase of Treasury Shares
On July 5, 2018, CompuGroup Medical SE announced a share buyback program for up to 500,000 shares, a total volume of up to € 23 million and a term until December 31, 2018. The program will begin on July 16, 2018 and is implemented through the repurchase of shares via the stock exchange (Xetra trading on the Frankfurt Stock Exchange) by a mandated securities trading bank. CompuGroup Medical SE thus makes use of the authorization granted by the Annual General Meeting on May 20, 2015, to buy back own shares. The repurchase will be financed from existing cash as well as the use of existing credit facilities. Although CompuGroup Medical SE may use the repurchased shares for all purposes in accordance with the authorization granted on May 20, 2015, the Company intends to redeem the majority of the repurchased shares or to use them for possible acquisition purposes.
Course of the share buyback
The start of the share buyback program was announced by CompuGroup MedicalSE on 05 July 2018. Starting July 16, 2018 CompuGroup Medical SE repurchased shares with the involvement of a financial institution exclusively via the stock exchange in electronic trading through the FRA Stock Exchange (Xetra). The program ended on October 17, because of completion of the volume of 23 million euro.
Disclosure Pursuent to Article 2 Sec. 1 of Commission Delegated Ragulation (EU) No. 2016/1052 supplementing Regulation (EU) No. 596/2014 (MAR) / Purchase of Treasury Shares
